Earlier this month, at the Endocrine Society’s annual conference in Boston, Danish pharma Novo Nordisk presented three years of data showing that their diabetes drug liraglutide helped obese and prediabetic patients lose weight without undue risk. Which is big, for a drug that’s been flagged for causing cancer.

Read more